Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Dec;36(12):1333-1335.
doi: 10.1007/s40263-022-00967-5. Epub 2022 Nov 4.

Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder"

Azmi Nasser  1 , Joseph T Hull  2 , Tesfaye Liranso  2 , Nicholas Fry  2 , Andrew J Cutler  3 , Jonathan Rubin  2 , Ann Childress  4
Affiliations
Comment

Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder"

Azmi Nasser et al. CNS Drugs. 2022 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AN, JTH, TL, NF, and JR are employees of Supernus Pharmaceuticals, Inc. AJC has received research support from Aevi Genomics, Akili Interactive, Arbor Pharmaceuticals, Ironshore Pharmaceuticals, Janssen, KemPharm, Lundbeck, Neos Therapeutics (now Aytu BioPharma), Neurovance, Noven, Otsuka, Purdue Canada, Rhodes Pharmaceuticals, Shire, Sunovion, Supernus Pharmaceuticals, Inc., Takeda, and Tris Pharma. He has received fees for consulting, advisory boards, and promotional speaking from Adlon Therapeutics, Aevi Genomics, Akili Interactive, Arbor Pharmaceuticals, Atentiv, Cingulate Therapeutics, Corium, Ironshore Pharmaceuticals, Janssen, Lundbeck, MedAvante-ProPhase, Neos Therapeutics (now Aytu BioPharma), NLS Pharmaceutics, Noven, Otsuka, Shire, Sunovion, Supernus Pharmaceuticals, Inc., Takeda, and Tris Pharma. He is an employee and board member of the Neuroscience Education Institute. AC has received research support from, served as a consultant or speaker for, or served on an advisory board for Allergan, Takeda (Shire), Emalex, Pearson, Akili, Arbor, Cingulate Therapeutics, Ironshore, Lumos, Aevi Genomic Medicine, Neos Therapeutics, Neurovance, Noven, Otsuka, Pfizer, Purdue, Adlon, Rhodes, Sunovion, Tris, KemPharm, Supernus Pharmaceuticals, Inc., the U.S. FDA, NLS Pharma, and Jazz.

Comment on

References

    1. Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/ hyperactivity disorder. CNS Drugs. 2022;36(8):897–915. doi: 10.1007/s40263-022-00938-w. - DOI - PMC - PubMed
    1. Singh A, Balasundaram MK. Comment on: “A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention deficit/hyperactivity disorder”. CNS Drugs. 2022. 10.1007/s40263-022-00966-6. - PubMed
    1. Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452–1466. doi: 10.1016/j.clinthera.2020.05.021. - DOI - PubMed
    1. Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN- 812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021;51(2):43–64. - PMC - PubMed
    1. Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684–700. doi: 10.1016/j.clinthera.2021.01.027. - DOI - PubMed

MeSH terms